Table 1.
Population characteristics: (total number of studies = 73).
| Variables | Numbers of Studies |
|---|---|
| Type of studies | |
| Preclinical | 32 |
| Clinical | 16 |
| Gray literature | 25 |
| Abstract a | 4 |
| Sample size | |
| Only one case | 7 |
| 1–10 patients | 7 |
| >10 | 2 |
| Included only patients with pancreatic cancer b | 5 |
| FGFR alterations | |
| FGFR alteration generic | 9 |
| FGFR2 fusion c | 4 |
| FGFR 2 amplification/rearrangement | 3 |
| Type of drugs | |
| Selective inhibitors pan-FGFR | |
| Erdafinitinib | 3 |
| Pemigatinib | 4 |
| Futibatinib | 2 |
| Selective inhibitors FGFR 1/2/3 | |
| Lirafugratinib | 1 |
| Fexagratinib | 2 |
| Monoclonal antibodies | |
| Aprutumab ixadotin | 1 |
| FGF ligand traps | |
| FB-1039 | 1 |
| Non-selective TKIs | |
| Pazopanib | 1 |
| Ponatinib | 1 |
| Dovitinib | 1 |
| Clinical outcomes (primary) | |
| Safety | 8 |
| Survival outcomes | 1 |
| Efficacy | 5 |
a included in clinical studies; b 2 abstract congress presentation and 3 case reports; c 2 studies reporting cases of fusion and rearrangement.